 |
PDBsum entry 6t41
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
6t41
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chain A:
E.C.2.7.11.22
- cyclin-dependent kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.2.7.11.23
- [RNA-polymerase]-subunit kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
[DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed RNA polymerase] + ADP + H+
|
 |
 |
 |
 |
 |
[DNA-directed RNA polymerase]
|
+
|
ATP
|
=
|
phospho-[DNA-directed RNA polymerase]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain B:
E.C.?
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
117:2894-2905
(2020)
|
|
PubMed id:
|
|
|
|
|
| |
|
A precisely positioned MED12 activation helix stimulates CDK8 kinase activity.
|
|
F.Klatt,
A.Leitner,
I.V.Kim,
H.Ho-Xuan,
E.V.Schneider,
F.Langhammer,
R.Weinmann,
M.R.Müller,
R.Huber,
G.Meister,
C.D.Kuhn.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The Mediator kinase module regulates eukaryotic transcription by phosphorylating
transcription-related targets and by modulating the association of Mediator and
RNA polymerase II. The activity of its catalytic core, cyclin-dependent kinase 8
(CDK8), is controlled by Cyclin C and regulatory subunit MED12, with its
deregulation contributing to numerous malignancies. Here, we combine in vitro
biochemistry, cross-linking coupled to mass spectrometry, and in vivo studies to
describe the binding location of the N-terminal segment of MED12 on the
CDK8/Cyclin C complex and to gain mechanistic insights into the activation of
CDK8 by MED12. Our data demonstrate that the N-terminal portion of MED12 wraps
around CDK8, whereby it positions an "activation helix" close to the
T-loop of CDK8 for its activation. Intriguingly, mutations in the activation
helix that are frequently found in cancers do not diminish the affinity of MED12
for CDK8, yet likely alter the exact positioning of the activation helix.
Furthermore, we find the transcriptome-wide gene-expression changes in human
cells that result from a mutation in the MED12 activation helix to correlate
with deregulated genes in breast and colon cancer. Finally, functional assays in
the presence of kinase inhibitors reveal that binding of MED12 remodels the
active site of CDK8 and thereby precludes the inhibition of ternary CDK8
complexes by type II kinase inhibitors. Taken together, our results not only
allow us to propose a revised model of how CDK8 activity is regulated by MED12,
but also offer a path forward in developing small molecules that target CDK8 in
its MED12-bound form.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|